MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

Group 1 - MiNK Therapeutics, Inc. has regained compliance with Nasdaq listing requirements, confirming it meets the minimum bid price and market value of listed securities [1] - The company specializes in the development of allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases [2] - MiNK is advancing a pipeline of both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery [2] Group 2 - The company is headquartered in New York, NY, and provides information relevant to investors through its website and social media channels [2] - The press release includes forward-looking statements regarding the potential benefits of iNKT cell therapies and future program goals, which are subject to various risks and uncertainties [3] - Investor and media contact information is provided for further inquiries [4]